Novo Holdings, the primary shareholder of Novo Nordisk, is targeting a doubling of size for its recent acquisition, Catalent, within five years. This move comes as the firm anticipates an increased ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE:NVO), hopes to double the size of its recently acquired contract drugmaker Catalent (NYSE:CTLT) over five years ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...